Potential MSN/ALK Fusion as Cancer Treatment (G4478)

Target Name: MSN

NCBI ID: G4478

Content of Review Report on MSN Target / Biomarker

MSN

Potential MSN/ALK Fusion as Cancer Treatment

MSN (Mesothelin-Specific Neoplasm) is a type of cancer that develops from the cells that line the body's various chambers, such as blood vessels, lungs, and intestines. This type of cancer is often difficult to treat, as it tends to spread quickly and can resist traditional forms of chemotherapy and radiation.

One potential drug target for MSN is MSN/ALK fusion. MSN/ALK fusion refers to a type of fusion protein that combines the properties of both MSN and ALK (Alexin锟絬m Liu kinase), a protein that is involved in cell signaling.

MSN/ALK fusion proteins have been shown to have a positive impact on the treatment of MSN. In particular, studies have shown that MSN/ALK fusion proteins can effectively inhibit the growth of MSN cells in cell culture and animal models of MSN.

One of the reasons why MSN/ALK fusion proteins are considered a potential drug target for MSN is because they can specifically target the cells that contain the MSN protein. This is important because MSN is often found in higher concentrations in cancer cells compared to healthy cells . By inhibiting the growth of MSN cells, MSN/ALK fusion proteins can potentially reduce the size and spread of MSN tumors.

Another potential mechanism by which MSN/ALK fusion proteins may work to treat MSN is by targeting the signaling pathways that are involved in the development and progression of MSN. Studies have shown that MSN cells are often characterized by activated signaling pathways, such as the PI3K /Akt pathway. By inhibiting this pathway, MSN/ALK fusion proteins can potentially reduce the growth and spread of MSN tumors.

In addition to their potential impact on MSN treatment, MSN/ALK fusion proteins also have the potential to serve as biomarkers for the disease. By detecting the expression of these proteins in MSN cells, researchers can potentially monitor the effectiveness of different treatments and identify potential biomarkers for MSN.

Overall, MSN/ALK fusion proteins are a promising potential drug target for MSN. Further research is needed to fully understand the mechanism of action of these proteins and to develop safe and effective treatments for this disease.

Protein Name: Moesin

Functions: Ezrin-radixin-moesin (ERM) family protein that connects the actin cytoskeleton to the plasma membrane and thereby regulates the structure and function of specific domains of the cell cortex. Tethers actin filaments by oscillating between a resting and an activated state providing transient interactions between moesin and the actin cytoskeleton (PubMed:10212266). Once phosphorylated on its C-terminal threonine, moesin is activated leading to interaction with F-actin and cytoskeletal rearrangement (PubMed:10212266). These rearrangements regulate many cellular processes, including cell shape determination, membrane transport, and signal transduction (PubMed:12387735, PubMed:15039356). The role of moesin is particularly important in immunity acting on both T and B-cells homeostasis and self-tolerance, regulating lymphocyte egress from lymphoid organs (PubMed:9298994, PubMed:9616160). Modulates phagolysosomal biogenesis in macrophages (By similarity). Participates also in immunologic synapse formation (PubMed:27405666)

The "MSN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MSN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets